Loss of the MMR component, MSH6, has been associated with increased tumour progression during temozolomide treatment in GBM (Cahill et al., 2007), and alterations of MSH2 expression can predict patient response to temozolomide therapy, with reduced expression correlating with decreased overall patient survival (McFaline-Figueroa et al., 2015). Here, MSH2 is linked to glioblastoma.